In 1990, Don Sawyer entered industry like many others do: as a sales representative.
DON SAWYER
Vice President, Managed Markets, AstraZeneca
In 1990, Don Sawyer entered industry like many others do: as a sales representative. But unlike most, he quickly gained prominence in industry for being one of the driving forces in developing AstraZeneca's novel strategic approach to the new Medicare Part D Benefit in 2006. As a result, today more than 90 percent of those in Medicare now have comprehensive drug coverage from Part D.
Make no mistake, this achievement was a "huge team effort," notes Sawyer, who believes that the foundation of great leadership lies in trust and confidence—two qualities Howard Swain, one of Sawyer's first district managers at Pfizer, observed early on when "Don's quick wit and great personality" set him apart from other prospective job candidates. "Despite being short on experience, Don was very long on the characteristics and qualities we and other managers thought would make him very successful in the pharma industry—or any other industry," Swain says.
And his prediction was right.
Currently, Sawyer leads the way for AstraZeneca in developing and implementing both brand and contract strategy for managed markets across the company's portfolio for the US business, in addition to running its US managed markets sales organization. And there's no stopping the 41-year-old former athlete and sports enthusiast who hopes that in 10 years he will be part of a "tremendous leadership team that will lead AstraZeneca through this period of tremendous industry change."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.